Translational Haematology

Description

Translational Hematology area is being developed as a reference site for molecular studies and clinical trials in hematology at the national and international levels. It participates actively in numerous cooperative groups of national or international level.

Within the preclinical area its current activities include finding new predictive response factors and biomarkers, customizing treatments and finally, searching for new Therapeutic Targets.

The research areas of Translational Hematology research group are as follows:

1. Identifying new molecular targets in total tumor cells or tumor-initiating cells that promote progression in Multiple Myeloma, Acute Leukemia, Lymphoma and Myeloproliferative Neoplasms.
2. Preclinical development in vivo and in vitro molecules or other therapeutic methods that could be used as candidates for new treatments in this group of diseases.
3. Identifying new diagnostic biomarkers and treatment response enabling precision medicine.
4. Studying the mechanisms of resistance to drugs antimyeloma and leukemia.
5. Development of research programs with NK cell therapies in hematological malignancies.
6. Consolidating clinical trials program Phases I, II and III in hematological tumors.
7. Developing a joint research program with the CNIO.